Skip to main content

Table 1 Summary of results for all tumour xenografts

From: Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)

Tumour model CNR calculated by FRI (AU)a FMT (nmol/l) VVF (%)b BVPD (BVPs/mm2)
MDA-MB435: melanoma 389 ± 72 (n = 10) 229 ± 90 (n = 4) 3.58 ± 0.9 (n = 4) 399 ± 36 (n = 6)
HT1080: fibrosarcoma 232 ± 99 (n = 11) 92 ± 65 (n = 5) 1.9 ± 0.7 (n = 4) 128 ± 38 (n = 6)
MCF7: adenocarcinoma 185 ± 57 (n = 9) 65 ± 50 (n = 6) 0.75 ± 0.5 (n = 4) 59 ± 10 (n = 6)
DU4475: adenocarcinoma 167 ± 79 (n = 13) 49 ± 22 (n = 4) 0.8 ± 0.5 (n = 4) 78 ± 16 (n = 6)
  1. Data are expressed as mean ± standard deviation. Note that the data generated by fluorescence imaging technologies (FRI, FMT) correlate well with in in vivo (VVF) and ex vivo (BVDP) surrogate markers of tumour angiogenesis. aCalculated 24 hours after intravenous injection of SIDAG. bMeasured using magnetic resonance imaging. AU, arbitrary units; BVP, blood vessel profile; BVPD: blood vessel profiles density; FMT, fluorescence-mediated tomography; FRI, fluorescence reflectance imaging; VVF, vascular volume fraction.